Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel composite core-shell nanoparticles as busulfan carriers.

A Layre1, P Couvreur, H Chacun

  • 1UMR CNRS 8612, Faculty of Pharmacy, Paris-Sud University, 5 rue Jean Baptiste Clément, 92296 Châtenay-Malabry, France.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|February 21, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications.

International journal of pharmaceutics·2019
Same author

Experimental cystic echinococcosis therapy: In vitro and in vivo combined 5-fluorouracil/albendazole treatment.

Veterinary parasitology·2017
Same author

Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications.

Parasitology research·2016
Same author

Characterization and comparison of two novel nanosystems associated with siRNA for cellular therapy.

International journal of pharmaceutics·2015
Same author

In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.

Nanomedicine (London, England)·2015
Same author

In vitro effect of 5-fluorouracil and paclitaxel on Echinococcus granulosus larvae and cells.

Acta tropica·2014

Novel composite core-shell nanoparticles were developed using poly(isobutylcyanoacrylate) (PIBCA) and poly(epsilon-caprolactone)-poly(ethylene glycol) (PCL-PEG) for enhanced busulfan drug delivery. This approach significantly increases drug loading and reduces immune response.

Area of Science:

  • Materials Science
  • Nanotechnology
  • Pharmaceutical Sciences

Background:

  • Busulfan is a crystalline drug with limited administration options.
  • Developing effective drug delivery systems is crucial for improving therapeutic outcomes.
  • Composite nanoparticles offer potential for enhanced drug encapsulation and controlled release.

Purpose of the Study:

  • To design and characterize novel composite core-shell nanoparticles for busulfan encapsulation.
  • To investigate the effect of polymer composition on nanoparticle properties and drug loading.
  • To evaluate the in vitro drug release and immunogenicity of the developed nanoparticles.

Main Methods:

  • Co-precipitation of poly(isobutylcyanoacrylate) (PIBCA) and poly(epsilon-caprolactone)-poly(ethylene glycol) (PCL-PEG) in various ratios.

Related Experiment Videos

  • Characterization of nanoparticle size, morphology, and surface charge using techniques like Zeta potential.
  • X-ray photoelectron spectroscopy (XPS) for surface composition analysis.
  • Quantification of drug loading efficiency and in vitro release using (3)H-labelled busulfan and liquid scintillation counting.
  • Assessment of complement activation to evaluate immunogenicity.

    • Main Results:

    • Composite core-shell nanoparticles with a PIBCA core and PCL-PEG shell were successfully synthesized.
    • The use of PIBCA in the core resulted in a 2-4 fold increase in busulfan drug loading compared to PCL-PEG nanoparticles alone.
    • XPS and Zeta potential analysis confirmed the preferential surface distribution of PCL-PEG, indicating a core-shell structure.
    • In vitro studies demonstrated controlled release of busulfan.
    • Composite nanoparticles showed significantly reduced complement consumption compared to PIBCA nanoparticles, due to the presence of PEG on the surface.

    Conclusions:

    • The developed PIBCA:PCL-PEG composite nanoparticles represent an innovative approach for busulfan administration.
    • The core-shell structure enhances drug loading efficiency.
    • Surface PEGylation of nanoparticles effectively reduces immunogenicity by minimizing complement activation.
    • These nanoparticles hold promise for improved busulfan-based therapies.